The GenFlex is a sample-to-result molecular diagnostic platform that includes sample collection, processing, amplification, and detection, the company said.
The new Series B investment was made by Northpond Ventures, with previously invested $20 million in the Australian diagnostics company.
Within diagnostics, the firm posted molecular diagnostics revenues of $178.5 million, up 9 percent from $164.3 million in fiscal Q1 2019.
The firms have agreed to develop infectious disease and women's heath testing assays using SpeeDx's proprietary technology.
The firm said it is turbocharging the lateral flow format with sensitivity and cost suitable for over-the-counter STI testing.
The firm will use funds from the round, led by the Midlands Engine Investment Fund, to develop its optical point-of-care diagnostic testing platform.
Cambridge, UK-based Sense Biodetection will use the funding to develop a portfolio of instrument-free, point-of-care molecular diagnostic tests.
The company said that the decline in revenues reflected lower industry-wide reimbursement rates under PAMA.
Antelope's founder said that being spun off by MyCartis gives his company the focus it needs to launch tests for use in homes and doctors' clinics.
The test is the first near-patient assay for M. genitalium, and can also guide treatment by detecting antibacterial resistance markers.